Table 3.
Clinical trials of mTOR inhibitors in combination with chemotherapy and targeted therapies in Pancreatic cancer.
| mTOR inhibitor | Patients | Drug combination | Phase | Trial Number |
|---|---|---|---|---|
| Everolimus | Pancreatic cancer | gemcltabine | I/II | NCT00560963 |
| BYL719 and exemestane | I | NCT02077933 | ||
| Pancreatic neuroendocrine tumors | 5-FU | III | NCT02246127 | |
| Octreotide acetate with or without bevacizumab | II | NCT01229943 | ||
| Pasireotide | II |
NCT01374451 NCT00804336 NCT01263353 |
||
| VEGFR/PDGFR dual inhibitor X-82 | I/II | NCT01784861 | ||
| Temozolomide | I/II | NCT00576680 | ||
| Sunitinib | II | NCT02315625 | ||
| Octreotide and metformin | I | NCT02294006 | ||
| Metastatic pancreatic cancer | Cetuximab and Capecitabine | I/II | NCT01077986 | |
| Rapamycin | Pancreatic cancer | Metformin | I/II | NCT02048384 |
| Sirolimus | Metastatic pancreatic cancer | Vismodegib | I | NCT01537107 |